Gut microbiome structure and metabolic activity in inflammatory bowel disease

被引:0
|
作者
Eric A. Franzosa
Alexandra Sirota-Madi
Julian Avila-Pacheco
Nadine Fornelos
Henry J. Haiser
Stefan Reinker
Tommi Vatanen
A. Brantley Hall
Himel Mallick
Lauren J. McIver
Jenny S. Sauk
Robin G. Wilson
Betsy W. Stevens
Justin M. Scott
Kerry Pierce
Amy A. Deik
Kevin Bullock
Floris Imhann
Jeffrey A. Porter
Alexandra Zhernakova
Jingyuan Fu
Rinse K. Weersma
Cisca Wijmenga
Clary B. Clish
Hera Vlamakis
Curtis Huttenhower
Ramnik J. Xavier
机构
[1] Broad Institute of MIT and Harvard,Department of Biostatistics
[2] Harvard School of Public Health,Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease
[3] Novartis Institute for Biomedical Research Inc.,Department of Immunology, K.G. Jebsen Coeliac Disease Research Centre
[4] Massachusetts General Hospital and Harvard Medical School,Center for Microbiome Informatics and Therapeutics
[5] Department of Gastroenterology and Hepatology,undefined
[6] University of Groningen and University Medical Center Groningen,undefined
[7] Department of Genetics,undefined
[8] University of Groningen and University Medical Center Groningen,undefined
[9] Novartis Institute for Biomedical Research Inc.,undefined
[10] Department of Pediatrics,undefined
[11] University of Groningen and University Medical Center Groningen,undefined
[12] University of Oslo,undefined
[13] Massachusetts Institute of Technology,undefined
来源
Nature Microbiology | 2019年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome—the molecular interface between host and microbiota—are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic ‘guilt by association’ (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome–metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.
引用
收藏
页码:293 / 305
页数:12
相关论文
共 50 条
  • [1] Gut microbiome structure and metabolic activity in inflammatory bowel disease
    Franzosa, Eric A.
    Sirota-Madi, Alexandra
    Avila-Pacheco, Julian
    Fornelos, Nadine
    Haiser, Henryj
    Reinker, Stefan
    Vatanen, Tommi
    Hall, A. Brantley
    Mallick, Himel
    Mclver, Lauren J.
    Sauk, Jenny S.
    Wilson, Robin G.
    Stevens, Betsy W.
    Scott, Justin M.
    Pierce, Kerry
    Deik, Amy A.
    Bullock, Kevin
    Imhann, Floris
    Porter, Jeffrey A.
    Zhernakova, Alexandra
    Fu, Jingyuan
    Weersma, Rinse K.
    Wijmenga, Cisca
    Clish, Clary B.
    Vlamakis, Hera
    Huttenhower, Curtis
    Xavier, Ramnik J.
    NATURE MICROBIOLOGY, 2019, 4 (02) : 293 - 305
  • [2] Author Correction: Gut microbiome structure and metabolic activity in inflammatory bowel disease
    Eric A. Franzosa
    Alexandra Sirota-Madi
    Julian Avila-Pacheco
    Nadine Fornelos
    Henry J. Haiser
    Stefan Reinker
    Tommi Vatanen
    A. Brantley Hall
    Himel Mallick
    Lauren J. McIver
    Jenny S. Sauk
    Robin G. Wilson
    Betsy W. Stevens
    Justin M. Scott
    Kerry Pierce
    Amy A. Deik
    Kevin Bullock
    Floris Imhann
    Jeffrey A. Porter
    Alexandra Zhernakova
    Jingyuan Fu
    Rinse K. Weersma
    Cisca Wijmenga
    Clary B. Clish
    Hera Vlamakis
    Curtis Huttenhower
    Ramnik J. Xavier
    Nature Microbiology, 2019, 4 : 898 - 898
  • [3] Gut microbiome structure and metabolic activity in inflammatory bowel disease (vol 4, pg 293, 2019)
    Franzosa, Eric A.
    Sirota-Madi, Alexandra
    Avila-Pacheco, Julian
    Fornelos, Nadine
    Haiser, Henry J.
    Reinker, Stefan
    Vatanen, Tommi
    Hall, A. Brantley
    Mallick, Himel
    McIver, Lauren J.
    Sauk, Jenny S.
    Wilson, Robin G.
    Stevens, Betsy W.
    Scott, Justin M.
    Pierce, Kerry
    Deik, Amy A.
    Bullock, Kevin
    Imhann, Floris
    Porter, Jeffrey A.
    Zhernakova, Alexandra
    Fu, Jingyuan
    Weersma, Rinse K.
    Wijmenga, Cisca
    Clish, Clary B.
    Vlamakis, Hera
    Huttenhower, Curtis
    Xavier, Ramnik J.
    NATURE MICROBIOLOGY, 2019, 4 (05) : 898 - 898
  • [4] Alteration of the Gut Microbiome in Inflammatory Bowel Disease
    Andoh, Akira
    Nishida, Atsushi
    DIGESTION, 2023, 104 (01) : 16 - 23
  • [5] Linking Inflammatory Bowel Disease Symptoms to Changes in the Gut Microbiome Structure and Function
    Hassouneh, Sayf Al-Deen
    Loftus, Mark
    Yooseph, Shibu
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [6] Dynamics of metatranscription in the inflammatory bowel disease gut microbiome
    Melanie Schirmer
    Eric A. Franzosa
    Jason Lloyd-Price
    Lauren J. McIver
    Randall Schwager
    Tiffany W. Poon
    Ashwin N. Ananthakrishnan
    Elizabeth Andrews
    Gildardo Barron
    Kathleen Lake
    Mahadev Prasad
    Jenny Sauk
    Betsy Stevens
    Robin G. Wilson
    Jonathan Braun
    Lee A. Denson
    Subra Kugathasan
    Dermot P. B. McGovern
    Hera Vlamakis
    Ramnik J. Xavier
    Curtis Huttenhower
    Nature Microbiology, 2018, 3 : 337 - 346
  • [7] Dynamics of the human gut microbiome in inflammatory bowel disease
    Halfvarson, Jonas
    Brislawn, Colin J.
    Lamendella, Regina
    Vazquez-Baeza, Yoshiki
    Walters, William A.
    Bramer, Lisa M.
    D'Amato, Mauro
    Bonfiglio, Ferdinando
    McDonald, Daniel
    Gonzalez, Antonio
    McClure, Erin E.
    Dunklebarger, Mitchell F.
    Knight, Rob
    Jansson, Janet K.
    NATURE MICROBIOLOGY, 2017, 2 (05):
  • [8] Dynamics of the human gut microbiome in inflammatory bowel disease
    Jonas Halfvarson
    Colin J. Brislawn
    Regina Lamendella
    Yoshiki Vázquez-Baeza
    William A. Walters
    Lisa M. Bramer
    Mauro D'Amato
    Ferdinando Bonfiglio
    Daniel McDonald
    Antonio Gonzalez
    Erin E. McClure
    Mitchell F. Dunklebarger
    Rob Knight
    Janet K. Jansson
    Nature Microbiology, 2
  • [9] Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
    Gubatan, John
    Holman, Derek R.
    Puntasecca, Christopher J.
    Polevoi, Danielle
    Rubin, Samuel J. S.
    Rogalla, Stephan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (43) : 7402 - 7422
  • [10] Vitamin D, the gut microbiome and inflammatory bowel disease
    Tabatabaeizadeh, Seyed-Amir
    Tafazoli, Niayesh
    Ferns, Gordon A.
    Avan, Amir
    Ghayour-Mobarhan, Majid
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2018, 23